Jomed/Fujisawa
This article was originally published in The Gray Sheet
Executive Summary
Licensing pact will allow Jomed to use Fujisawa Pharmaceutical's Prograf (tacrolimus) immunosuppressant drug on stents to help prevent restenosis. In November, Beringen, Switzerland-based Jomed inked an agreement with Alcove to use its proprietary nano-porous ceramic stent surface technology. Clinical trials of Jomed's drug eluting stent will commence by year-end...